Robert A Kratzke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3161377/publications.pdf

Version: 2024-02-01

53	2,218	236925	214800
papers	citations	25 h-index	47 g-index

53	53	53	2654
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC. Lung Cancer Management, 2022, 11, LMT54.	1.5	3
2	4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer. Investigational New Drugs, 2021, 39, 636-643.	2.6	5
3	Synchronous breast carcinoma and peritoneal mesothelioma. Breast Journal, 2021, 27, 550-552.	1.0	1
4	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. Translational Lung Cancer Research, 2021, 10, 826-838.	2.8	5
5	eIF4F Inhibition Sensitizes Nonâ€Small Cell Lung Cancer Cells to a Topoisomerase II Inhibitor. FASEB Journal, 2021, 35, .	0.5	0
6	A Turning Point for Mesothelioma Therapy. JCO Oncology Practice, 2021, , OP2100608.	2.9	1
7	Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities. Clinical Lung Cancer, 2020, 21, e164-e168.	2.6	3
8	Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clinical Lung Cancer, 2020, 21, 553-561.e1.	2.6	29
9	Survival of Lung Cancer Patients Dependent on the LOH Status for DMP1, ARF, and p53. International Journal of Molecular Sciences, 2020, 21, 7971.	4.1	2
10	Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vesicular Stomatitis Virus Expressing Interferon-Î² in Preclinical Models of Non-Small Cell Lung Cancer. Translational Oncology, 2020, 13, 100782.	3.7	14
11	Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma. Cancer Chemotherapy and Pharmacology, 2020, 85, 425-432.	2.3	6
12	Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. Cancer Chemotherapy and Pharmacology, 2019, 83, 387-391.	2.3	5
13	Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer. Cancer Gene Therapy, 2019, 26, 157-165.	4.6	9
14	JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Therapy, 2019, 26, 411-418.	4.6	60
15	LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 66-73.e6.	2.6	19
16	Smoking, Sex, and Nonâ€“Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). Journal of the National Cancer Institute, 2018, 110, 734-742.	6.3	32
17	4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma. Investigational New Drugs, 2018, 36, 217-229.	2.6	9
18	Meet the new boss: lung cancer staging. Journal of Thoracic Disease, 2018, 10, 1329-1331.	1.4	1

#	Article	IF	Citations
19	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 416-427.	2.8	11
20	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist, 2017, 22, 189-198.	3.7	9
21	Oncolytic Viral Therapy for Mesothelioma. Frontiers in Oncology, 2017, 7, 179.	2.8	37
22	Targeting eukaryotic protein translation in mesothelioma. Translational Lung Cancer Research, 2017, 6, 343-349.	2.8	4
23	Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma. Oncotarget, 2017, 8, 63096-63109.	1.8	7
24	A 10-Gene Yin Yang Expression Ratio Signature for Stage IA and IB Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 2150-2160.	1.1	14
25	Detection of Occult Micrometastases in Patients With Clinical Stage I Nonâ€“Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). Journal of Clinical Oncology, 2016, 34, 1484-1491.	1.6	40
26	Epigenetics of lung cancer. Translational Research, 2015, 165, 74-90.	5.0	131
27	Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma. Genes and Cancer, 2015, 6, 144-152.	1.9	27
28	Vesicular stomatitis virus expressing interferon-Î² is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget, 2015, 6, 33165-33177.	1.8	87
29	Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives. Anticancer Research, 2015, 35, 5211-7.	1.1	4
30	Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells. Investigational New Drugs, 2014, 32, 598-603.	2.6	21
31	Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosphoramidate Pronucleotide (4Ei-1) Results in Chemosensitization to Gemcitabine and Induced eIF4E Proteasomal Degradation. Molecular Pharmaceutics, 2013, 10, 523-531.	4.6	69
32	Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC. Journal of Thoracic Oncology, 2013, 8, 1142-1147.	1.1	12
33	miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma. Chest, 2013, 144, 1632-1643.	0.8	50
34	Does miR-1 Play a Role in Malignant Pleural Mesothelioma Development and Progression?: Response. Chest, 2013, 144, 1971-1972.	0.8	0
35	Targeting Eukaryotic Translation in Mesothelioma Cells with an eIF4E-Specific Antisense Oligonucleotide. PLoS ONE, 2013, 8, e81669.	2.5	32
36	Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. Pharmacogenomics, 2012, 13, 1009-1021.	1.3	26

#	Article	IF	Citations
37	A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307. Journal of Thoracic Oncology, 2010, 5, 1655-1661.	1.1	115
38	Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II. Investigational New Drugs, 2010, 28, 20-25.	2.6	28
39	Alternative fuel metabolism in lung cancer by metabolic phenotyping. FASEB Journal, 2009, 23, 678.1.	0.5	0
40	Response to the Methylation Inhibitor Dihydro-5-azacytidine in Mesothelioma Is Not Associated with Methylation of p16INK4a: Results of Cancer and Leukemia Group B 159904. Journal of Thoracic Oncology, 2008, 3, 417-421.	1.1	14
41	Ras Pathway Activation in Malignant Mesothelioma. Journal of Thoracic Oncology, 2007, 2, 789-795.	1.1	31
42	Translational control: A target for cancer therapy. Cancer Letters, 2007, 258, 1-8.	7.2	40
43	Molecular pathways in malignant pleural mesothelioma. Cancer Letters, 2006, 239, 183-189.	7.2	38
44	Repression of Cap-Dependent Translation Attenuates the Transformed Phenotype in Nonâ€“Small Cell Lung Cancer Both In vitro and In vivo. Cancer Research, 2006, 66, 4256-4262.	0.9	50
45	Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B. Clinical Cancer Research, 2005, 11, 2300-2304.	7.0	250
46	Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells. Cancer Research, 2004, 64, 7479-7485.	0.9	67
47	Gene Expression Profiling Identifies Matriptase Overexpression in Malignant Mesothelioma. Chest, 2004, 125, 1843-1852.	0.8	90
48	Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer, 2002, 38, 131-136.	2.0	80
49	The pathogenesis of mesothelioma. Seminars in Oncology, 2002, 29, 2-17.	2.2	330
50	Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer. Lung Cancer, 2001, 32, 27-38.	2.0	21
51	Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Therapy, 2000, 7, 1421-1425.	4.6	41
52	Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene, 1998, 16, 3087-3095.	5.9	125
53	Immunohistochemical Analysis of the p16INK4 Cyclin-Dependent Kinase Inhibitor in Malignant Mesothelioma. Journal of the National Cancer Institute, 1995, 87, 1870-1875.	6.3	113